New York City-based Synergy Pharmaceuticals submitted a supplemental New Drug Application for Trulance. Here’s what you should know. 1. Trulance was FDA approved in adults with chronic idiopathic ...

Synergy Pharmaceuticals, a developer of gastrointestinal disorder and disease drugs, has announced its appointment of gastroenterologist Gail M. Comer, MD, as chief medical officer, according to a ...

Synergy Pharmaceuticals Inc. is seeing growing investor interest due to its potential treatment for bowel syndrome, said a Cantor Fitzgerald analyst who started coverage of the drug developer with a ...

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NAS: SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for ...

There is a basic bodily function that all people have, yet most do not want to see, hear or smell – let alone talk about. But bowel movements are an important indicator of health, and for the ...

April 30 (Reuters) - Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, ...

The Food and Drug Administration on Thursday approved New York City-based Synergy Pharmaceuticals’ drug for chronic idiopathic constipation. Trulance is a once-daily treatment that works locally in ...

Synergy Pharmaceuticals (SGYP) has made some progress since my initiation article, but the company also had some missteps along the way. The biotech bear market has negatively affected Synergy's share ...

Synergy Pharmaceuticals (SGYP) delivered a slight EPS and revenue beat last week. Trulance’s prescription growth isn’t exactly where I thought it would be at this point in time, but there is progress ...